Precise prediction of cerebrospinal fluid amyloid beta protein for early Alzheimer's disease detection using multimodal data

Abstract

Abstract Alzheimer's disease (AD) constitutes a neurodegenerative disorder marked by a progressive decline in cognitive function and memory capacity. The accurate diagnosis of this condition predominantly relies on cerebrospinal fluid (CSF) markers, notwithstanding the associated burdens of pain and substantial financial costs endured by patients. This study encompasses subjects exhibiting varying degrees of cognitive impairment, encompassing individuals with subjective cognitive decline, mild cognitive impairment, and dementia, constituting a total sample size of 82 participants. The primary objective of this investigation is to explore the relationships among brain atrophy measurements derived from magnetic resonance imaging, atypical electroencephalography (EEG) patterns, behavioral assessment scales, and amyloid β‐protein (Aβ) indicators. The findings of this research reveal that individuals displaying reduced Aβ1‐42/Aβ‐40 levels exhibit significant atrophy in the frontotemporal lobe, alongside irregularities in various parameters related to EEG frequency characteristics, signal complexity, inter‐regional information exchange, and microstates. The study additionally endeavors to estimate Aβ1‐42/Aβ‐40 content through the application of a random forest algorithm, amalgamating structural data, electrophysiological features, and clinical scales, achieving a remarkable predictive precision of 91.6%. In summary, this study proposes a cost‐effective methodology for acquiring CSF markers, thereby offering a valuable tool for the early detection of AD.

Keywords

• amyloid beta protein
• cerebrospinal fluid
• EEG
• MRI